Anika Therapeutics continues to expand addressable market for Tactoset

Anika Therapeutics announced that it has received an additional 510(k) clearance from FDA for Tactoset Injectable Bone Substitute. This new indication expands the use of Tactoset to be combined with autologous bone marrow aspirate, BMA. "Tactoset, a regenerative solutions product, continues to be a key growth driver within our joint preservation and restoration portfolio, as it is uniquely positioned to address unmet needs in patients with insufficiency fractures and poor-quality bone including cysts where augmenting hardware, such as suture anchors, gives surgeons additional confidence in their repair constructs," said Cheryl R. Blanchard, PhD, President and CEO, Anika Therapeutics. "This new FDA clearance for mixing Tactoset with BMA provides a product with improved regenerative capacity and showcases Anika’s commitment to developing unique solutions that are meaningful to our customers and their patients. It also further reinforces our confidence that we can increase Tactoset’s addressable market to well beyond $100 million by creating a new market for hardware augmentation. The BMA clearance, together with the release of enhanced cannulas and our distribution of the Marrow Cellution Bone Marrow Aspiration Needle announced today, highlight our continued investment in differentiated products that expand and reinforce our regenerative solutions portfolio and enhance growth and profitability for our shareholders."